A meta-analysis shows that 1/3 of the IBD patients do not respond to anti-TNF treatment, and more than 1/3 patients receiving TNF antagonists experience a loss of response or intolerance to treatment (1). The gene discussed is TNF; the disease is inflammatory bowel disease.